Originally published In Press as doi:10.1074/jbc.M111915200 on January 10, 2002
J. Biol. Chem., Vol. 277, Issue 11, 9155-9159, March 15, 2002
A New Substrate Specificity for Acyl Transferase Domains of the
Ascomycin Polyketide Synthase in Streptomyces
hygroscopicus*
Christopher D.
Reeves
,
Loleta M.
Chung,
Yaoquan
Liu,
Qun
Xue§,
John R.
Carney,
W. Peter
Revill, and
Leonard
Katz
From Kosan Biosciences, Inc., Hayward, California 94545
Received for publication, December 14, 2001, and in revised form, January 9, 2002
 |
ABSTRACT |
Ascomycin (FK520) is a structurally complex
macrolide with immunosuppressant activity produced by
Streptomyces hygroscopicus. The biosynthetic origin of
C12-C15 and the two methoxy groups at C13 and C15 has been unclear. It
was previously shown that acetate is not incorporated into C12-C15 of
the macrolactone ring. Here, the acyl transferase (AT) of domain 8 in
the ascomycin polyketide synthase was replaced with heterologous ATs by
double homologous recombination. When AT8 was replaced with
methylmalonyl-CoA-specific AT domains, the strains produced
13-methyl-13-desmethoxyascomycin, whereas when AT8 was replaced with a
malonyl-specific domain, the strains produced 13-desmethoxyascomycin.
These data show that ascomycin AT8 does not use malonyl- or
methylmalonyl-CoA as a substrate in its native context. Therefore, AT8
must be specific for a substrate bearing oxygen on the
carbon.
Feeding experiments showed that [13C]glycerol is
incorporated into C12-C15 of ascomycin, indicating that both modules 7 and 8 of the polyketide synthase use an extender unit that can be
derived from glycerol. When AT6 of the 6-deoxyerythronolide B synthase
gene was replaced with ascomycin AT8 and the engineered gene was
expressed in Streptomyces lividans, the strain produced 6-deoxyerythronolide B and 2-demethyl-6-deoxyerythronolide B. Therefore, although neither malonyl-CoA nor methylmalonyl-CoA is a
substrate for ascomycin AT8 in its native context, both are substrates
in the foreign context of the 6-deoxyerythronolide B synthase.
Thus, we have demonstrated a new specificity for an AT domain in
the ascomycin polyketide synthase and present evidence that specificity
can be affected by context.
 |
INTRODUCTION |
Ascomycin (FK520) is closely related to tacrolimus (FK506), which
is used to prevent xenograft rejection in human patients. Dosing of
tacrolimus is difficult because metabolism varies between patients and
different co-administered drugs (1-3). Because initial metabolism is
due to cytochrome P450-mediated demethylation of the 13-methoxy group
(4, 5), we wished to replace the 13-methoxy group with a hydrogen or
methyl group and determine whether this increased metabolic
stability. Because these analogues could not be obtained by
current chemical methods, we sought the
desired analogues of ascomycin modified at C13 (Fig. 1) using
PKS1 engineering (6, 7).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Structures of ascomycin and engineered
analogues. The extender unit incorporated by module 8 of the
ascomycin PKS and the engineered versions thereof are highlighted with
gray in each structure.
|
|
The macrolactone precursor of ascomycin is biosynthesized by a large
PKS complex consisting of a loading module for a shikimate-derived starter unit; 10 modules for malonyl, methylmalonyl, or other PKS
extender units; and a peptide synthetase module for addition of
pipecolate (8-13). FK520 and FK506 have methoxy groups at C13 and C15,
which could be derived by post-PKS hydroxylation followed by
O-methylation or by direct incorporation of an extender unit with an oxygen at the
carbon. Feeding of
[13C2]acetate was reported to label C8-C9 and
C20-C23 of the macrolactone ring, as expected, but not C12-C15 in
either FK520 or FK506 (8). A [1-13C]erythrose feed, used
to establish that the dihydroxycyclohexane starter unit is derived from
shikimate, unexpectedly labeled C12 and C14, implying that the extender
unit is more readily derived from erythrose than from acetate.
Sequence analysis of the ascomycin gene cluster from Streptomyces
hygroscopicus (14) showed that it contains close homologues of the
genes in the FK506 cluster (9-11) that encode the three PKS subunits,
the peptide synthetase, the lysine cyclodeaminase, the C9 hydroxylase,
the 31-O-methyltransferase, and the putative 9-hydroxyl
oxidase. In the flanking regions of the FK520 cluster, additional genes
were found with proposed roles in synthesis of precursors, including a
putative methoxymalonyl-ACP precursor for the 13- and 15-methoxy
groups of FK520 (14).
The choice of extender unit by a modular PKS system is determined by
the acyl transferase (AT) domain of each module (6, 15-17). Comparison
of methylmalonyl-CoA- and malonyl-CoA-specific AT domain sequences
shows that they cluster into two groups with sequence motifs that
diverge according to the specificity of the domain (15). More recently,
AT domains specific for ethylmalonyl units have been identified, and
they are most closely related to the methylmalonyl-specific domains
(18). In addition, there is circumstantial evidence that some domains
are specific for an extender unit with oxygen on the
carbon
(19-21). Despite the availability of the Escherichia coli
malonyl-CoA:ACP transacylase crystal structure (22) and extensive
biochemical experiments with both the rat fatty acid synthase
and several bacterial PKSs (23-27), the structural basis for AT domain
substrate specificity has not been established.
Here we describe replacement of the ascomycin AT8 domain with AT
domains specific for malonyl or methylmalonyl extender units, resulting
in the production of analogues modified at C13 and showing that
ascomycin AT8 is specific for an extender unit bearing oxygen on the
carbon. Precursor labeling experiments showed that ascomycin PKS
modules 7 and 8 use an extender unit that can be derived from glycerol.
In addition, we show that the specificity of this AT domain can be
altered by placing it into a foreign PKS context.
 |
EXPERIMENTAL PROCEDURES |
Strains and Media--
The ascomycin-producing strain, S. hygroscopicus ATCC 14891, was plated on SY medium (10 g of soluble
starch, 2 g of yeast extract, and 20 g of agar per liter) to
prepare spore stocks and grown in TSBGM (tryptic soy broth supplemented
with 50 mM TES buffer, pH 7, and 1% glucose) for
production of ascomycin or its analogues. Growth and transformation of
Streptomyces lividans K4-114 has been described previously
(28). Use of the phage vector KC515 followed established procedures
(28).
Preparation of Phage Carrying AT Replacement Cassettes--
PKS
module 8 was isolated as a 4.6-kb SphI fragment from cosmid
pKOS65-C31 (14) and cloned into Litmus28 (New England Biolabs), and the orientation with a unique SacI site proximal to the
SpeI site of the polylinker was used (pKOS60-21). A
synthetic linker was ligated between the SpeI and
SacI sites and then subsequently ligated between the
SphI and AflII sites to give pKOS60-29, which was
used as a template to isolate regions flanking AT8 by PCR. The PCR
mixtures for all reactions described herein contained (50 µl, total
volume) 1 µl of template (either diluted plasmid DNA, undiluted
genomic DNA, or high-titer phage stock), 10× Pfu buffer, 10×
z-deoxynucleotide triphosphate mix (200 µM each
deoxynucleotide triphosphate except 100 µM dGTP and 100 µM 7-deaza-dGTP; Roche Molecular Biochemicals), 10%
Me2SO, 400 nM of each primer, and 1 µl of
cloned Pfu polymerase (Stratagene). Reactions were cycled 25-30 times at 95 °C for 30 s, 60 °C for 30 s, and
72 °C for 2 min. To amplify the 5'-flanking region, the forward
primer was 5'-CGACTCACTAGTGGGCAGATCTGGC-3', and one of two reverse
primers was used: 1) 5'-CACGCCTAGGCCGGTCGGTCTCGGGCCAC-3', which
introduced an AvrII site near the 3' end of the ketoacyl
synthase domain, or 2) 5'-GCGGCTAGCTGCTCGCCCATCGCGGGATGC-3', which
introduced an NheI site near the 5' end of the AT boundary.
These PCR products were cloned as SpeI to AvrII
and SpeI to NheI fragments into Litmus28 and
Litmus38, respectively, to give pKOS60-37-4 and pKOS60-37-2. The
3'-flanking region was isolated using a forward primer
(5'-GATGTACAGCTCGAGTCGGCACGCCCGGCCGCATC-3') that introduced an
XhoI site at the AT/dehydratase boundary plus a
BsrGI site to facilitate the construction; the reverse
primer was 5'-CGACTCACTTAAGCCATGCATCC-3'. This PCR product was isolated as a BsrGI to AflII fragment and ligated into
pKOS60-37-4 cut with Acc65I and AflII or
pKOS60-37-2 cut with BsrGI and AflII, giving
pKOS60-39-13 and pKOSS60-39-1, respectively.
Heterologous AT domains were obtained by PCR using primers that
introduced AvrII and XhoI or NheI and
XhoI sites at the 5' and 3' ends, respectively. Each
heterologous AT was cloned into pKOS60-39-13
(AvrII-XhoI) or pKOS60-39-1
(NheI-XhoI) to create a series of AT replacement
cassettes. Each replacement cassette was isolated as a BglII
to NsiI fragment and ligated to KC515 DNA cut with
BamHI and PstI, and the ligation mixture was
introduced into S. lividans TK24 by transfection. The
resulting plaques were purified, and high-titer phage stocks were
prepared as described previously (28). Recombinant phage preparations
were checked by PCR using a pair of primers annealing within the
dehydratase/keto reductase-flanking sequence.
Construction of Strains with AT8 Replaced by Heterologous
ATs--
Spores of S. hygroscopicus (107) were
suspended in Difco nutrient broth, heat-shocked at 50 °C for 10 min,
and mixed with an equal number of plaque-forming units of recombinant
phage in Difco nutrient broth. The mixture was spread on R2YE plates
(28), and after an overnight incubation at 30 °C, plates were
overlaid with 1.25 mg of thiostrepton suspended in 1 ml of
H2O. After 7-10 days, sporulating colonies were
streaked on SY agar containing 50 µg/ml thiostrepton. Colonies were
picked from these plates after about 5 days and macerated in 200 µl
of H2O using a microfuge pestle. Half the suspension was
inoculated into a 25 × 150-mm tube with two 4-mm glass beads and
5 ml of TSBGM; the other half was inoculated into the same medium with
50 µg/ml thiostrepton. After 2-3 days, a 1.5-ml sample of each
thiostrepton-containing culture was harvested for total DNA isolation,
and a 0.75-ml sample was prepared for LC-MS analysis by adding
an equal volume of MeCN and clarifying by centrifugation. DNA was
isolated by the SDS, proteinase K, phenol method (28) and analyzed by
Southern blot hybridization using the digoxigenin labeling and
detection kits supplied by Roche Molecular Biochemicals. Each culture
grown without thiostrepton was spread on an SY agar plate to obtain
spores to screen for the second recombination event.
Selected spore preparations from the nonselective propagation plates
above were titered and spread on several plates at about 100-200
colonies/plate. When colonies were sufficiently sporulated, they were
replica-plated onto SY agar plates containing 50 µg/ml thiostrepton.
After 4-5 days, putative thioS recombinants were
identified and clonally isolated. These were grown in 5-ml TSBGM tube
cultures for 3 days, and the broth was extracted as described above for
LC-MS analysis (see below). Strains producing 13-DMA or 13-MDMA were
designated KOS45-170 and KOS60-135, respectively.
Precursor Labeling
Studies--
[13C2]Glycine and
[13C3]glycerol were obtained from Cambridge
Isotope Laboratories. [13C2]Glycolate, a
mixture of ethyl [13C2]bromoacetate (Aldrich;
98% 13C; 1.0 g), sodium acetate (1.0 g), and
anhydrous N,N-dimethylformamide (15 ml), was
stirred at 80 °C for 3 h. Water was added, and the mixture was
extracted three times with Et2O. The combined organic layers were washed twice with H2O, washed once with brine,
and dried over Na2SO4. After removal of
solvent, a clear oil (0.45 g) was obtained. 1H NMR
(CDCl3):
4.59 (2H, dd, J = 149, 4.8 Hz), 4.23 (2H, qd, J = 7.2, 3.2 Hz), 2.16 (3H, s), 1.29 (3H, t, J = 7.2 Hz). The acetate was dissolved in MeOH
(15 ml), 0.5 M LiOH (15 ml) was added, and the mixture was
stirred overnight at room temperature. After neutralization with 2 N HCl, the mixture was extracted twice with ether. The
aqueous layer was dried under high vacuum to give [13C2]lithium glycolate (508 mg; containing
some sodium acetate and NaCl). 1H NMR (D2O):
3.88 (2H, dd, J = 143.6, 4.4 Hz). 13C
NMR (D2O):
179.1 (d, J = 55 Hz), 60.3 (d, J = 55 Hz).
[methyl-13C]Methoxyacetic acid:ethyl
diazoacetate (1.8 ml) was added dropwise to a stirred solution of
Rh2(OAc)4 (10 mg) in [13C]methanol (Isotec; 99 atom% 13C;
1.0 g). After 4 h, the mixture was diluted with 10 ml of
hexanes and filtered through a 1 cm plug of silica gel. The silica was washed with 3:1 hexanes/ether, and the eluates were combined and concentrated to give 1.35 g of ethyl
[methyl-13C]methoxyacetate as a colorless
liquid. 1H NMR (CDCl3):
4.24 (2H, q,
J = 7.2 Hz), 4.03 (2H, d, JCH = 4.8 Hz), 3.45 (3H, d, JCH = 142 Hz), 1.31 (3H,
t, J = 7.2 Hz). The ester was dissolved in 2 ml of MeOH
and treated with 10 ml of 6 N NaOH for 12 h. The
mixture was extracted three times with CH2Cl2,
and then the aqueous phase was acidified to below pH 2 using
concentrated HCl and diluted with 100 ml of saturated aqueous NaCl before continuous extraction with ether for 24 h. The ether extract was dried over MgSO4, filtered, and evaporated to
yield 1.5 g of an oil. Bulb-to-bulb distillation under reduced
pressure yielded clean
[methyl-13C]methoxyacetic acid (0.70 g).
1H NMR (CDCl3):
4.09 (2H, d,
JCH = 4.8 Hz), 3.48 (3H, d,
JCH = 142 Hz).
[methyl-13C]Methoxymalonic
acid:5-diazo-Meldrum's acid (2 g), [13C]methanol (2 g),
Rh2(OAc)4 (250 mg), and toluene (25 ml) were mixed in an Ace pressure tube. The capped tube was heated at 140 °C
for 2 h, the reaction was filtered, and the filtrate was
evaporated. The residue was dissolved in H2O and extracted
three times with EtOAc. The combined organic layers were dried over
MgSO4, filtered, and evaporated to yield an oil (1.3 g),
which was identified as a mixture of dimethyl methoxymalonate and
monomethyl methoxymalonate. The oil was dissolved in MeOH (5 ml), 6 N NaOH (10 ml) was added, and the mixture was left
overnight at room temperature. After cooling on ice, the mixture was
acidified to pH < 1 with HCl and filtered. The filtrate was dried
under high vacuum to yield a yellow solid (1 g). To remove the
inorganic salt, the solid was extracted three times with acetone; the
acetone extracts were evaporated to give methoxymalonic acid as a solid
(0.65 g). 1H NMR (acetone-d6):
4.47 (1H, d,
J = 4 Hz), 3.46 (3H, d, J = 143 Hz).
13C NMR (acetone-d6):
167.0, 79.9, 57.5 (enriched).
Cultures grown in TSBGM were harvested at 24 h, washed twice, and
resuspended in 100 mM MES, pH 6.0, 1% glucose to the
original culture volume. The resting cell suspension was shaken in
baffled flasks at 30 °C and 175 rpm. The 13C-labeled
precursors were added in three equal portions at 24, 36, and 48 h
to obtain 0.5 g/liter final concentration. Resting cell cultures were
harvested at 56 h by adding half the volume of the culture of
MeOH. The resulting broth/extract was clarified by centrifugation and
loaded at 25 ml/min onto a column of Diaion HP-20ss pre-equilibrated in
MeOH-H2O (2:1). The column volume was
the
volume of the broth/extract. The column was eluted at 8 ml/min with
MeOH-H2O at ratios of 1:2 (2 column volumes), 1:1 (4 column
volumes), 7:3 (4 column volumes), and 9:1 (4 column volumes). The 9:1
eluent was concentrated to give crude ascomycin, which was
chromatographed over Bond-Elut ODS solid phase extraction cartridges by
eluting with MeOH-H2O (9:1). This material was suitable for
NMR analysis.
Expression of DEBS with AT6 Replaced by Ascomycin AT8--
The
Streptomyces expression vector pKAO127 containing the SCP2*
replicon and the DEBS genes expressed via the actI promoter and actII-ORF4 transcription activator were described
previously (29). Constructs with SpeI and PstI
sites engineered at the eryAT6 boundaries have also been described
previously (6). The ascomycin AT8 was isolated by PCR with primers that
introduced a SpeI site at the 5' boundary and an
NsiI site at the 3' boundary. The PCR product was cloned
into Litmus28 to give pKOS38-178, which was checked by sequencing, and
subsequently inserted between the engineered SpeI and
PstI sites flanking DEBS AT6. This was assembled into the
DEBS expression construct pKOS38-187. The construct was introduced into
S. lividans K4-114 by standard protoplast transformation (28), and the transformants were cultured in R5 medium for production of the 6-DEB analogue.
LC-MS Analysis--
Samples were analyzed by on-line extraction
by LC-MS using a system comprised of a 10 port, 2 position switching
valve/injector, Beckman System Gold HPLC, an Alltech evaporative light
scattering detector, and a PE SCIEX API100 LC-mass spectrometer
equipped with an atmospheric pressure chemical ionization source. For
ascomycin analogue analyses, whole cultures were extracted by adding 1 volume of MeCN and clarified by centrifugation. Sample (250 µl) was
loaded onto an Upchurch 4.3 × 10 mm ODS guard column that had
been pre-equilibrated for 1 min with 0.1% acetic acid at 1 ml/min,
with the eluate being diverted to waste. At 30 s postinjection a
linear gradient to 1:1 MeCN-H2O (0.1% acetic acid) over 1 min was started, with the eluate still diverted to waste. At 2 min, the
direction of flow through the guard column was reversed, and the eluent
was diverted onto a Metachem Inertsil ODS-3 column (5 µm; 4.6 × 150 mm) at 50 °C pre-equilibrated with 1:1 MeCN-H2O
(0.1% acetic acid). A linear gradient from 50% to 100% MeCN (0.1%
acetic acid) at 1 ml/min over 5 min and then 100% MeCN (0.1% acetic
acid) for 4 min was monitored by evaporative light scattering and mass
spectrometry. For 6-DEB and 2-demethyl-6-DEB, 100 µl of clarified
whole broth was loaded onto the guard column after a 1 min
pre-equilibration with H2O at 1 ml/min. At 30 s
postinjection, a linear gradient to 15% MeCN over 1 min was initiated.
At 2 min, the direction of flow through the guard column was reversed,
and the eluent was diverted onto a Metachem Inertsil ODS-3 column (5 µm; 4.6 × 150 mm) pre-equilibrated with 15% MeCN. A linear
gradient from 15% to 100% MeCN at 1 ml/min over 6 min and then 100%
MeCN for 3 min was monitored by evaporative light scattering and mass spectrometry.
 |
RESULTS |
Replacement of AT8 in the Ascomycin PKS--
We previously
hypothesized that AT8 of the ascomycin PKS selects the unusual
precursor methoxymalonyl-ACP leading to direct incorporation of the
methoxy group at C13 (14). To explore this, ascomycin AT8 was replaced
with heterologous ATs of known specificity by double homologous
recombination using the phage vector KC515 as shown in Fig.
2. Between 10 and 100 thiostrepton-resistant colonies were obtained after infection with
recombinant phages, whereas KC515 alone gave no thiostrepton-resistant
colonies. Ten isolates each of lysogens from the rapamycin AT3 or
erythromycin AT2 construct were analyzed in detail. None produced
detectable ascomycin or related products, consistent with insertion of
the phage into a gene essential for ascomycin production. Southern blot
hybridization experiments (using XhoI or Acc65I
digestion of genomic DNA) showed that of the erythromycin AT2 lysogens, seven arose by recombination at the ketoacyl synthase 8 sequence, and
three arose by recombination at the dehydratase 8/keto reductase 8 sequence, whereas of the rapamycin AT3 lysogens, eight recombined at
the dehydratase 8/keto reductase 8 sequence, one recombined at the
ketoacyl synthase 8, and one apparently recombined at the dehydratase
1/keto reductase 1 sequence, which is 98% identical over 1 kb with
keto reductase 8/dehydratase 8. Three lysogens from the
malonyl-specific rapamycin AT12 construct also did not produce FK520,
and the expected first crossover event was verified using PCR.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Diagram showing how S. hygroscopicus strains were engineered to replace AT8 in the
ascomycin PKS with AT domains of other specificity. Each AT
replacement cassette was delivered on the KC515 phage vector, and
thiostrepton-resistant recombinants were selected. Isolates that had
crossed over at either the ketoacyl synthase 8 or dehydratase 8 sequence were observed by Southern blot analyses. Analysis of the
thioS isolates indicated that both types of second
crossover events occurred, giving wild-type revertants or strains
containing the heterologous AT replacement, which produced the
predicted ascomycin analogue. See "Experimental Procedures" for
details.
|
|
After growth in the absence of selection, thioS colonies
appeared at a frequency of about 0.3%, half of which produced
ascomycin and had therefore reverted to wild-type. With the exception
of one thioS recombinant that produced no ascomycin-related
compound, the remaining thioS recombinants produced a
compound with an LC retention time and atomic mass consistent with
either 13-DMA (for the rapamycin AT12 replacement) or 13-MDMA (for the
rapamycin AT3 and erythromycin AT2 replacements). The overall
statistics indicated little bias for recombination via one flanking
sequence over the other. After growing selected strains in
laboratory-scale stirred-tank fermenters and purifying the ascomycin
analogues, structures were verified by mass spectrometry and NMR
analyses.2 For the rapamycin
AT3 replacement strain, only 13-MDMA was produced, and the relative
stereochemistry of the 13-methyl group was the same as that of the
13-methoxy group of ascomycin. Thus, the
-methyl epimerization
activity that occurs in rapamycin module 3 does not appear to reside on
the AT domain, consistent with previous work (23). The 13-DMA and
13-MDMA analogues were produced at levels about 5% of parental
ascomycin titers (50 mg/liter), which is better than most PKS
engineering results (6). For the rapamycin AT12 replacement strain,
13-DMA was the predominant product, but a small amount (~5% of the
total) of ascomycin was also observed, even after two rounds of clonal
isolation. A summary of the products identified in cultures of the
engineered strains is presented in Table
I.
Incorporation of 13C-labeled Precursors into
Ascomycin--
It was reported previously that
[1,2-13C]acetate can be incorporated into the
macrolactone ring carbons C8, C9, and C20-C23 but not C12-C15 in either
ascomycin or FK506 (8). To explore the origin of C12-C15 further, the
incorporation of potential 13C-labeled precursors
([13C2]glycolate,
[methyl-13C]methoxyacetate,
[methyl-13C]methoxymalonate,
[13C2]glycine, and
[13C3]glycerol) was evaluated by
13C NMR experiments (Table
II). No significant enrichment of the O-methyl carbon atoms was seen if either
[methyl-13C]methoxyacetate or
[methyl-13C]methoxymalonate was fed. In
addition, no detectable coupled signals at C12-C15 were seen after
feeding glycolate. Glycine gave weak coupled signals at C12-C15 and
additional weak signals for the O-methyl carbons (at C13,
C15, and C31), presumably because of metabolism via the one-carbon
pool. On the other hand, glycerol feeding gave unequivocal signals
resulting from 1JC-C for C12-C13 and
C14-C15, indicating intact incorporation of two-carbon units at these
positions (Table II).
Expression of DEBS with AT6 Replaced by Ascomycin
AT8--
Replacement of DEBS AT6 by the malonyl-specific rapamycin AT2
and expression in S. lividans was previously shown to give
production of 2-demethyl-6-DEB instead of 6-DEB (6). To further study the ascomycin AT8 domain, the same fusion junctions engineered in this
previous construct were used to replace DEBS AT6 with ascomycin AT8.
LC-MS analysis of S. lividans cultures expressing this
construct revealed that 6-DEB and 2-demethyl-6-DEB (Fig. 3) were produced at ~7 and 3 mg/liter,
respectively, or 10-20% the level of 6-DEB produced by S. lividans cultures expressing the wild-type DEBS genes. No
2-methoxy-2-demethyl-6-DEB was observed. Thus, ascomycin AT8 in this
foreign PKS context, expressed in a strain that does not contain the
methoxymalonyl precursor, selects either malonyl-CoA or
methylmalonyl-CoA as alternative substrate relatively efficiently.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Structure of 6-DEB and potential
analogues. S. lividans expressing DEBS produces
predominantly 6-DEB. S. lividans expressing DEBS with AT6
replaced by ascomycin AT8 produces 6-DEB and 2-demethyl-6-DEB. No
2-methoxy-2-demethyl-6-DEB was detected. The portion of the molecules
arising from incorporation by DEBS module 6 is boxed.
|
|
 |
DISCUSSION |
The results of AT8 replacement in the ascomycin PKS have proven
that module 8 uses a precursor other than malonyl-CoA or
methylmalonyl-CoA. Moreover, we have shown that C12-C15 arise by
sequential incorporation of an extender unit that can be derived from
glycerol, consistent with our previous proposal, based on gene
homologies, that the direct precursor comes from the glycolytic pathway
(14). Recent results have confirmed that replacement of AT7 with ATs
specific for malonyl, methylmalonyl, or ethylmalonyl extenders gave the predicted 15-desmethoxy
analogue.3 Two possible
reasons glycolate was not incorporated are that it was not taken up by
the cells or that one of the activities needed to convert it to
glycerate (e.g. tartronate semialdehyde synthase) was absent
from S. hygroscopicus under the growth conditions used.
Our results are consistent with the proposal that methoxymalonyl-ACP is
the substrate used by modules 7 and 8 (14). The substrate is more
likely to be a methoxymalonyl thioester rather than a hydroxymalonyl
thioester for the following reasons. First, aside from fkbM,
the assigned 31-O-methyltransferase gene, fkbG is
the only other methyltransferase gene found in the cluster (14). It is
unlikely that FkbG methylates both the 13- and 15- hydroxyl groups of a
post-PKS intermediate because methyltransferases are known to have very
tight substrate specificity. Second, the sequence of FkbG is most
similar to two methyltransferases encoded in clusters for macrolides
with a methoxy group at an
carbon and is more similar to plant
caffeoyl-CoA methyltransferases than to any of the enzymes known to
methylate a post-PKS macrolide intermediate (14). This is consistent
with FkbG methylating a precursor to the extender unit before its
incorporation into the polyketide chain. Finally, if hydroxymalonyl
units were incorporated at these positions, the polyketide would
rearrange to form the hemiketal isomers known to be favored following
demethylation of these methoxy groups by mammalian liver CYP3A (4, 5), and this could interfere with subsequent biosynthetic steps. Our previous proposal that the substrate is methoxymalonyl-ACP instead of
methoxymalonyl-CoA was based on the presence of an unusual ACP gene
(fkbJ) in the set of five genes believed to encode the synthesis of this extender unit (14). If this hypothesis is correct,
methoxymalonyl-specific AT domains may recognize features of the
unusual ACP as an additional way to maintain tight substrate specificity.
The choice of precursor by a given AT domain is governed by its
relative selectivity for the available substrates and the effective
concentrations of those substrates. Clearly, there is an adequate
supply of both malonyl-CoA and methylmalonyl-CoA in S. hygroscopicus during ascomycin production because these precursors are incorporated by other modules of the ascomycin PKS. Despite this,
AT8 in its native ascomycin PKS context discriminates against these
substrates because the corresponding analogues have never been observed
from the wild-type strain. In addition, when the fkbG gene
was disrupted, no ascomycin-related structures were detected,4 showing that AT8
(and AT7) discriminates against malonyl-CoA or methylmalonyl-CoA in its
native context.
Extender unit specificity is usually tight, although there are examples
of relaxed specificity, such as module 4 of the epothilone PKS, which
incorporates either malonyl or methylmalonyl units (30, 31), and
modules in the ascomycin and monensin PKSs, which can incorporate
ethylmalonyl or methylmalonyl units (8, 32). Rapamycin AT12, which is
specific for malonyl-CoA in its native context, accepted the
methoxymalonyl substrate to some extent, i.e. about 5% of
the product from the engineered strain was ascomycin in the ascomycin
PKS context. When ascomycin AT8 was placed into the context of DEBS
module 6, both methylmalonyl-CoA and malonyl-CoA were used efficiently
as substrates, even though the domain rejects these substrates in the
native context, as discussed above. Recently, genes encoding
methoxymalonyl-ACP biosynthesis from the ansamitocin gene cluster of
Actinosynnema pretiosum were co-expressed along with the
engineered DEBS genes in S. lividans, and the resulting
strain produced
2-methoxy-2-demethyl-6-DEB.5
This shows that ascomycin AT8 maintains its original substrate preference in this foreign context. On the other hand, our results also
suggest that changing the context of an AT domain can affect substrate
selectivity. We hypothesize that external steric forces on a domain
after folding and assembly of the PKS complex can change the
conformation of a domain sufficiently to affect its specificity.
Replacement of a short segment of amino acids toward the C terminus of
AT domains, which lies outside the homology with E. coli
transacylase and is probably on the exterior of the domain, also has
been shown to alter specificity (24). Perhaps this region is important
for the interaction of the AT domain with the rest of the PKS complex
and thus can affect specificity by the mechanism hypothesized here.
Although primary sequence motifs have been identified that play a role
in substrate specificity (15, 33), it has not yet been possible to
identify sequence motifs correlated with specificity for the
methoxymalonyl substrate. Indeed, AT domains specific for
methoxymalonyl substrates appear to have evolved from either malonyl-specific domains, as in the case of the ascomycin PKS, or from
methylmalonyl-specific domains, as in the case of the niddamycin and
soraphen PKSs (18, 34).
 |
FOOTNOTES |
*
This work was supported in part by SBIR Grant
1R43AI46206-01A1 from the National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Kosan Biosciences,
Inc., 3832 Bay Center Place, Hayward, CA 94545. Tel.: 510-732-8400; Fax: 510-732-8401; E-mail: reeves@kosan.com.
§
Present address: Darden Graduate School of Business Administration,
University of Virginia, Charlottesville, VA 22906.
Published, JBC Papers in Press, January 10, 2002, DOI 10.1074/jbc.M111915200
2
J. Carney, R. Arslanian, E. Woo, and G. Ashley, manuscript in preparation.
3
A. Schirmer, W. P. Revill, and L. Katz,
unpublished data.
4
M. Trujillo, W. P. Revill, and L. Katz,
unpublished data.
5
Y. Kato, L. Bai, Q. Xue, W. P. Revill,
T.-W. Yu, and H. G. Floss, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
PKS, polyketide
synthase;
ACP, acyl carrier protein;
AT, acyl transferase (appended
number designates the module where the domain is from);
LC-MS, liquid
chromatography-mass spectrometry;
13-DMA, 13-desmethoxyascomycin;
13-MDMA, 13-methyl-13-desmethoxyascomycin;
6-DEB, 6-deoxyerythronolide
B;
DEBS, deoxyerythronolide B synthase;
thioS, thiostrepton-sensitive.
 |
REFERENCES |
| 1.
|
Sewing, K. F.
(1994)
Transplant. Proc.
26,
3267-3269[Medline]
[Order article via Infotrieve]
|
| 2.
|
Iwasaki, K.,
Matsuda, H.,
Nagase, K.,
Shiraga, T.,
Tokuma, Y.,
and Uchida, K.
(1993)
Res. Commun. Chem. Pathol. Pharmacol.
82,
209-216[Medline]
[Order article via Infotrieve]
|
| 3.
|
Lampen, A.,
Christians, U.,
Guengerich, F. P.,
Watkins, P. B.,
Kolars, J. C.,
Bader, A.,
Gonschior, A. K.,
Dralle, H.,
Hackbarth, I.,
and Sewing, K. F.
(1995)
Drug Metab. Dispos.
23,
1315-1324[Abstract]
|
| 4.
|
Iwasaki, K.,
Shiraga, T.,
Matsuda, H.,
Nagase, K.,
Tokuma, Y.,
Hata, T.,
Fujii, Y.,
Sakuma, S.,
Fujitsu, T.,
and Fujikawa, A.
(1995)
Drug Metab. Dispos.
23,
28-34[Abstract]
|
| 5.
|
Shiraga, T.,
Matsuda, H.,
Nagase, K.,
Iwasaki, K.,
Noda, K.,
Yamazaki, H.,
Shimada, T.,
and Funae, Y.
(1994)
Biochem. Pharmacol.
47,
727-735[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
McDaniel, R.,
Thamchaipenet, A.,
Gustafsson, C., Fu, H.,
Betlach, M.,
and Ashley, G.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1846-1851[Abstract/Free Full Text]
|
| 7.
|
Katz, L.
(1997)
Chem. Rev.
97,
2557-2576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Byrne, K. M.,
Shafiee, A.,
Nielson, J.,
Arison, B.,
Monaghan, R. L.,
and Kaplan, L.
(1993)
Dev. Ind. Microbiol.
32,
29-45
|
| 9.
|
Motamedi, H.,
Shafiee, A.,
Cai, S. J.,
Streicher, S. L.,
Arison, B. H.,
and Miller, R. R.
(1996)
J. Bacteriol.
178,
5243-5248[Abstract/Free Full Text]
|
| 10.
|
Motamedi, H.,
Cai, S. J.,
Shafiee, A.,
and Elliston, K. O.
(1997)
Eur. J. Biochem.
244,
74-80[Medline]
[Order article via Infotrieve]
|
| 11.
|
Motamedi, H.,
and Shafiee, A.
(1998)
Eur. J. Biochem.
256,
528-534[Medline]
[Order article via Infotrieve]
|
| 12.
|
Nielsen, J. B.,
Hsu, M. J.,
Byrne, K. M.,
and Kaplan, L.
(1991)
Biochemistry
30,
5789-5796[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Shafiee, A.,
Motamedi, H.,
Dumont, F. J.,
Arison, B. H.,
and Miller, R. R.
(1997)
J. Antibiot. (Tokyo)
50,
418-423[Medline]
[Order article via Infotrieve]
|
| 14.
|
Wu, K.,
Chung, L.,
Revill, W. P.,
Katz, L.,
and Reeves, C. D.
(2000)
Gene (Amst.)
251,
81-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Haydock, S. F.,
Aparicio, J. F.,
Molnar, I.,
Schwecke, T.,
Khaw, L. E.,
Konig, A.,
Marsden, A. F.,
Galloway, I. S.,
Staunton, J.,
and Leadlay, P. F.
(1995)
FEBS Lett.
374,
246-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kuhstoss, S.,
Huber, M.,
Turner, J. R.,
Paschal, J. W.,
and Rao, R. N.
(1996)
Gene (Amst.)
183,
231-236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Oliynyk, M.,
Brown, M. J.,
Cortes, J.,
Staunton, J.,
and Leadlay, P. F.
(1996)
Chem. Biol.
3,
833-839[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Kakavas, S. J.,
Katz, L.,
and Stassi, D.
(1997)
J. Bacteriol.
179,
7515-7522[Abstract/Free Full Text]
|
| 19.
|
Haber, A.,
Johnson, R. D.,
and Rinehart, K. L. J.
(1977)
J. Am. Chem. Soc.
99,
3541-3544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Hill, A. M.,
Harris, J. P.,
and Siskos, A. P.
(1998)
Chem. Commun.
1998,
2361-2362[CrossRef]
|
| 21.
|
Ono, M.,
Sakuda, S.,
Ikeda, H.,
Furihata, K.,
Nakayama, J.,
Suzuki, A.,
and Isogai, A.
(1998)
J. Antibiot. (Tokyo)
51,
1019-1028[Medline]
[Order article via Infotrieve]
|
| 22.
|
Serre, L.,
Verbree, E. C.,
Dauter, Z.,
Stuitje, A. R.,
and Derewenda, Z. S.
(1995)
J. Biol. Chem.
270,
12961-12964[Abstract/Free Full Text]
|
| 23.
|
Khosla, C.,
Gokhale, R. S.,
Jacobsen, J. R.,
and Cane, D. E.
(1999)
Annu. Rev. Biochem.
68,
219-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Lau, J., Fu, H.,
Cane, D. E.,
and Khosla, C.
(1999)
Biochemistry
38,
1643-1651[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Marsden, A. F.,
Caffrey, P.,
Aparicio, J. F.,
Loughran, M. S.,
Staunton, J.,
and Leadlay, P. F.
(1994)
Science
263,
378-380[Abstract/Free Full Text]
|
| 26.
|
Rangan, V. S.,
and Smith, S.
(1997)
J. Biol. Chem.
272,
11975-11978[Abstract/Free Full Text]
|
| 27.
|
Rangan, V. S.,
Serre, L.,
Witkowska, H. E.,
Bari, A.,
and Smith, S.
(1997)
Protein Eng.
10,
561-566[Abstract/Free Full Text]
|
| 28.
|
Kieser, T.,
Bibb, M. J.,
Buttner, M. J.,
Chater, K. F.,
and Hopwood, D. A.
(2000)
Practical Streptomyces Genetics
, The John Innes Foundation, Norwich, United Kingdom
|
| 29.
|
Kao, C. M.,
Katz, L.,
and Khosla, C.
(1994)
Science
265,
509-512[Abstract/Free Full Text]
|
| 30.
|
Julien, B.,
Shah, S.,
Ziermann, R.,
Goldman, R.,
Katz, L.,
and Khosla, C.
(2000)
Gene (Amst.)
249,
153-160[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Tang, L.,
Shah, S.,
Chung, L.,
Carney, J.,
Katz, L.,
Khosla, C.,
and Julien, B.
(2000)
Science
287,
640-642[Abstract/Free Full Text]
|
| 32.
|
Liu, H.,
and Reynolds, K. A.
(1999)
J. Bacteriol.
181,
6806-6813[Abstract/Free Full Text]
|
| 33.
|
Reeves, C. D.,
Murli, S.,
Ashley, G. W.,
Piagentini, M.,
Hutchinson, C. R.,
and McDaniel, R.
(2001)
Biochemistry
40,
15464-15470[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Schupp, T.,
Toupet, C.,
Cluzel, B.,
Neff, S.,
Hill, S.,
Beck, J. J.,
and Ligon, J. M.
(1995)
J. Bacteriol.
177,
3673-3679[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Sun, H. Hong, M. Samborskyy, T. Mironenko, P. F. Leadlay, and S. F. Haydock
Organization of the biosynthetic gene cluster in Streptomyces sp. DSM 4137 for the novel neuroprotectant polyketide meridamycin
Microbiology,
December 1, 2006;
152(12):
3507 - 3515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Haydock, A. N. Appleyard, T. Mironenko, J. Lester, N. Scott, and P. F. Leadlay
Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449
Microbiology,
October 1, 2005;
151(10):
3161 - 3169.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.